Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QuinoMit Q10 fluid (ubiquinol)
- Development stage
- Phase 2
- Lead developer
- MSE Pharmazeutika
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
QuinoMit Q10 fluid is a liquid coenzyme Q10 emulsion developed by MSE Pharmazeutika, containing ubiquinol as its active ingredient. Ubiquinol is the bioactive, reduced form of coenzyme Q10, which serves as a critical component of the mitochondrial electron transport chain, supporting ATP synthesis and maintaining mitochondrial membrane integrity. The formulation utilizes ultra-small droplets to significantly enhance bioavailability, achieving approximately twice the absorption of standard capsule-based ubiquinol. It is currently being evaluated in Phase II clinical trials for the treatment of Parkinson's disease, with a focus on patients carrying mitochondrial genetic risk variants such as Parkin or PINK1 mutations. The ubiquinol used in the formulation is sourced from Kaneka and produced through a biological fermentation process without genetic engineering.
- Brand names
- QuinoMit Q10 fluidQuinoMit® Q10 Fluid
- Other names
- reduced coenzyme Q10ubiquinol-10ubiquinol10ubiquinol 10CoQ10CoQ-10CoQ 10coenzyme Q10 emulsion
02
Targets
bc1 complex (Cytochrome bc1 complex (plasmodium))SDH (Mitochondrial electron transport chain complex II)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on QuinoMit Q10 fluid (ubiquinol).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QuinoMit Q10 fluid (ubiquinol).